诺和锐特充治疗妊娠期糖尿病的临床效果观察(1)
摘 要：目的 探究在妊娠期糖尿病患者中采用诺和锐特充治疗的临床疗效。方法 选取我院2015年2月～2017年2月收治的妊娠期糖尿病患者84例，随机分为对照组41例和治疗组43例。对照组采用诺和灵R注射治疗，治疗组采用诺和锐特充治疗，比较两组患者的临床治疗效果和治疗前后的血糖变化情况。结果 治疗组治疗总有效率为95.35%，高于对照组的63.41%，差异具有统计学意义(P<0.05)。两组患者在治疗后血糖指标下降，其中治疗组的餐后2 h血糖和HOMA-IR下降程度高于对照组，HOMA-β的下降程度低于对照组，差异均具有统计学意义(P<0.05)。结论 采用诺和锐特充治疗妊娠期糖尿病患者，可以提高临床治疗效果，改善血糖变化情况，值得临床推广应用。
关键词：诺和锐特充；妊娠期糖尿病；血糖；HOMA-IR；HOMA-β
中图分类号：R714.25 文献标识码：B DOI：10.3969/j.issn.1006-1959.2018.08.069
, 百拇医药
文章编号：1006-1959(2018)08-0186-02
Clinical Observation on the Treatment of Gestational Diabetes Mellitus with Novoterol
WANG Rong
(Department of Obstetrics and Gynecology，Zhabei Central Hospital，Jing'an District，Shanghai 200070，China)
Abstract：Objective To investigate the clinical efficacy of Novoterol in the treatment of gestational diabetes mellitus.Methods 84 cases of gestational diabetes mellitus admitted in our hospital from February 2015 to February 2017 were randomly divided into control group(n=41)and treatment group(n=43).The control group was treated with Novolin R injection，and the treatment group was treated with Novoterol.The clinical effects and the changes of blood glucose before and after treatment were compared between the two groups.Results The total effective rate in the treatment group was 95.35%，which was higher than 63.41% in the control group，the difference was statistically significant(P<0.05).The blood glucose levels of the two groups decreased after treatment.The 2 hour postprandial blood glucose and HOMA-IR decreased in the treatment group was higher than that in the control group，and the decrease in HOMA-β was lower than that in the control group，the difference was statistically significant(P<0.05).Conclusion The treatment of gestational diabetes mellitus with Novoterol can improve the clinical therapeutic effect and improve the change of blood glucose.It is worthy of clinical application.
, 百拇医药
Key words：Novoterol；Gestational diabetes mellitus；Blood sugar；HOMA-IR；HOMA-β
妊娠期糖尿病(gestational diabetes mellitus，GDM)是指妊娠前孕婦的糖代谢正常或有潜在糖耐量减退、妊娠期出现糖尿病的情况[1]。女性在妊娠期间容易患有妊娠期糖尿病，该疾病的发病率越来越高，该疾病一旦发作将会引发较多的并发症，不仅仅对患者产生较大痛苦，还可能会导致胎儿畸形的情况[2]。所以该疾病的治疗已经成为重中之重，其中诺和锐特充是一种临床上刚刚应用的胰岛素，该药物在吸收上较好，并已经慢慢开始在临床上应用[3]。本研究选取我院2015年2月～2017年2月84例妊娠期糖尿病患者，采用诺和锐特充治疗，从而探讨该药物在妊娠期糖尿病患者中的临床治疗效果，现报道如下。
1资料与方法
1.1一般资料 选取上海市静安区闸北中心医院2015年2月～2017年2月84例妊娠期糖尿病患者，本研究经过医院伦理会批准。根据随机数字表法将患者分为对照组和治疗组。对照组41例，年龄24～34岁，平均年龄(29.43±4.32)岁；初产妇30例，经产妇11例。治疗组43例，年龄24～35岁，平均年龄(30.21±5.98)岁；初产妇32例，经产妇11例。两组患者一般资料相比，差异无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(王荣)
关键词：诺和锐特充；妊娠期糖尿病；血糖；HOMA-IR；HOMA-β
中图分类号：R714.25 文献标识码：B DOI：10.3969/j.issn.1006-1959.2018.08.069
, 百拇医药
文章编号：1006-1959(2018)08-0186-02
Clinical Observation on the Treatment of Gestational Diabetes Mellitus with Novoterol
WANG Rong
(Department of Obstetrics and Gynecology，Zhabei Central Hospital，Jing'an District，Shanghai 200070，China)
Abstract：Objective To investigate the clinical efficacy of Novoterol in the treatment of gestational diabetes mellitus.Methods 84 cases of gestational diabetes mellitus admitted in our hospital from February 2015 to February 2017 were randomly divided into control group(n=41)and treatment group(n=43).The control group was treated with Novolin R injection，and the treatment group was treated with Novoterol.The clinical effects and the changes of blood glucose before and after treatment were compared between the two groups.Results The total effective rate in the treatment group was 95.35%，which was higher than 63.41% in the control group，the difference was statistically significant(P<0.05).The blood glucose levels of the two groups decreased after treatment.The 2 hour postprandial blood glucose and HOMA-IR decreased in the treatment group was higher than that in the control group，and the decrease in HOMA-β was lower than that in the control group，the difference was statistically significant(P<0.05).Conclusion The treatment of gestational diabetes mellitus with Novoterol can improve the clinical therapeutic effect and improve the change of blood glucose.It is worthy of clinical application.
, 百拇医药
Key words：Novoterol；Gestational diabetes mellitus；Blood sugar；HOMA-IR；HOMA-β
妊娠期糖尿病(gestational diabetes mellitus，GDM)是指妊娠前孕婦的糖代谢正常或有潜在糖耐量减退、妊娠期出现糖尿病的情况[1]。女性在妊娠期间容易患有妊娠期糖尿病，该疾病的发病率越来越高，该疾病一旦发作将会引发较多的并发症，不仅仅对患者产生较大痛苦，还可能会导致胎儿畸形的情况[2]。所以该疾病的治疗已经成为重中之重，其中诺和锐特充是一种临床上刚刚应用的胰岛素，该药物在吸收上较好，并已经慢慢开始在临床上应用[3]。本研究选取我院2015年2月～2017年2月84例妊娠期糖尿病患者，采用诺和锐特充治疗，从而探讨该药物在妊娠期糖尿病患者中的临床治疗效果，现报道如下。
1资料与方法
1.1一般资料 选取上海市静安区闸北中心医院2015年2月～2017年2月84例妊娠期糖尿病患者，本研究经过医院伦理会批准。根据随机数字表法将患者分为对照组和治疗组。对照组41例，年龄24～34岁，平均年龄(29.43±4.32)岁；初产妇30例，经产妇11例。治疗组43例，年龄24～35岁，平均年龄(30.21±5.98)岁；初产妇32例，经产妇11例。两组患者一般资料相比，差异无统计学意义(P>0.05)，具有可比性。, http://www.100md.com(王荣)